Research
Adherence
Oral GLP-1 receptor agonists (e.g., orforglipron) provide comparable efficacy to injectable formulations while improving accessibility by eliminating cold-chain requirements.
If you prefer pills over injections, oral GLP-1 medications like orforglipron are a viable option. They work similarly to shots but are taken daily by mouth, which may help you stick with the treatment longer. They are also easier to store and distribute globally.
ModerateSupportsMEDIUM confidence
Orforglipron, the first effective non-peptide oral GLP-1RA... achieved mean bodyweight reductions of up to approximately 9.6% at 72 weeks... These outcomes position orforglipron as comparable to injectable GLP-1RAs while offering the convenience of oral administration without food or water restrictions
Why this rating
Based on Phase 2 and 3 trials.
Source
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies
Ioannis Lempesis et al. · Metabolism Open · 2026
DOI 10.1016/j.metop.2026.100463
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Triple receptor agonists (GLP-1/GIP/Glucagon) such as retatrutide achieve superior weight loss (20-24%) compared to single or dual agonists by synergistically combining satiety, nutrient partitioning, and increased energy expenditure.Moderate
- Combining amylin analogs (e.g., cagrilintide) with GLP-1 agonists (e.g., semaglutide) achieves weight loss (20-22%) through distinct neuroendocrine circuits, offering a tolerability advantage over single agents.Moderate
- Body composition-targeted agents (e.g., bimagrumab) preserve or increase lean mass while reducing fat mass, addressing the functional decline associated with rapid weight loss.Moderate
Related findings · Adherence
- Regular physical activity (at least 150 minutes/week of moderate-intensity) reduces all-cause and cardiovascular mortality by 20-30% and lowers the risk of type 2 diabetes by 25-35%.Strong
- Increasing physical activity from a sedentary lifestyle to an active one in middle adulthood significantly reduces the risk of coronary events compared to remaining sedentary.Strong
- Resistance exercise is the only intervention capable of consistently restoring muscle function and strength in sarcopenia, partially overcoming age-related anabolic resistance.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →